Delix Therapeutics
Matt Gorman is a CFO for high growth companies in the life sciences. He is the Founder and Owner of CFgO, a finance, accounting, and strategy group. Working as a strategic partner with the CEO and management teams, Matt supports and guides companies through significant value inflection points including equity and debt financings, corporate partnering, IPO support, and M&A support.
Matt has more than a decade of experience in leadership roles in the life sciences industry and previously worked for Fortune 50 and publicly traded companies. Matt is a certified public accountant and holds a B.A in accounting from Stonehill College and an M.B.A. from the University of Massachusetts Isenberg School of Management.
This person is not in any teams
This person is not in any offices
Delix Therapeutics
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.